Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer
Jacob Taylor(The University of Texas Southwestern Medical Center), Yair Lotan(Southwestern Medical Center), Seth Lerner(Baylor College of Medicine), Facundo Davaro(Moffitt Cancer Center), Jeffrey Howard(The University of Texas Southwestern Medical Center), Elizabeth Dyer(Penn State Milton S. Hershey Medical Center), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Stephen Harrington(Penn State Milton S. Hershey Medical Center), M. Roumiguié(Institut universitaire du cancer de Toulouse Oncopole), Ian M. McElree(Vanderbilt University Medical Center), Peter C. Black(University of British Columbia), Jayanthi Raman(University of Technology Sydney), Roger Li(Unknown), Gary D. Steinberg(Rush University Medical Center), Anna J. Black(University of British Columbia), Pratik Kanabur(Carilion Clinic), Wei Shen Tan, Solomon L. Woldu(The University of Texas Southwestern Medical Center), Vignesh T. Packiam(Rutgers, The State University of New Jersey), William J. Huang(NYU Langone Health), Drupad Annapureddy(The University of Texas Southwestern Medical Center), Michael A. O’Donnell(University of Iowa Health Care), Mark A. Preston(Brigham and Women's Hospital), Kendrick Yim(Brigham and Women's Hospital)
Cited by 27
Related Papers
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|793
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
|World Journal of Urology|2016|471
Spectrum of diverse genomic alterations define non–clear cell renal carcinoma subtypes
|Nature Genetics|2014|359